• Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

  NCT05130268

  CompletedInterventionalPhase 4Updated Jan 28, 2025
• Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)

  NCT01026090

  TerminatedInterventionalPhase 4Updated Aug 6, 2014
• Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation

  NCT01070667

  Unknown statusInterventionalPhase 4Updated Feb 22, 2010
• Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy

  NCT01151137

  TerminatedInterventionalPhase 3Updated Oct 26, 2012
• Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation

  NCT01199081

  CompletedInterventionalPhase 4Updated Jun 7, 2013
• A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

  NCT00174785

  CompletedInterventionalPhase 3Updated Jan 12, 2010

ClinicalTrials.gov ID

NCT07270848

Lead Sponsor

Inha University HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

1,898Estimated

Last Update Posted

Dec 22, 2025Actual

Start Date

Jan 1, 2026Estimated

Primary Completion Date

Jun 2028Estimated

Completion Date

Dec 2028Estimated

Official Title

A Multicenter Prospective Study on the Efficacy, Safety, and Quality of Life Improvements of Dronedarone for Early Rhythm Control in Atrial Fibrillation

Brief Summary

The purpose of this study is to compare two commonly used types of medicine for treating atrial fibrillation (also called AF), a condition that causes an irregular heart rhythm. This study is for adults who have been diagnosed with AF within the past year.

Researchers want to find out which medicine is more effective, safer, and provides a better quality of life for patients needing to control their heart rhythm.

Participants who agree to join the study will be randomly assigned (like flipping a coin) to one of two groups:

Group 1: Will receive the medicine Dronedarone.

Group 2: Will receive a standard medicine from the 'Class Ic' group (such as flecainide or propafenone).

The study will follow participants for at least 12 months. Researchers will compare how well each medicine works to prevent AF from coming back. They will also carefully track any side effects and changes in participants' quality of life during the study.

Detailed Description

This study is a prospective, multicenter, randomized, open-label trial designed to address a common clinical question in the management of recent-onset atrial fibrillation (AF). Following recent evidence supporting the benefits of an early rhythm-control strategy, both dronedarone and Class Ic antiarrhythmic drugs (AADs) are widely used. However, there is a lack of large-scale, prospective, randomized data directly comparing the efficacy, safety, and quality of life outcomes between these two treatment strategies in this specific population.

The primary objective of the DRIVE-AF study is to compare the clinical outcomes of dronedarone versus standard Class Ic AADs (flecainide or propafenone) in patients with AF diagnosed within the past year.

Approximately 1,898 participants will be enrolled at 16 centers in the Republic of Korea. Eligible participants who provide informed consent will be randomized in a 1:1 ratio to receive either dronedarone or a Class Ic AAD (investigator's choice of flecainide or propafenone).

All participants will be followed for a minimum of 12 months. Efficacy will be primarily assessed by the recurrence of atrial fibrillation. Safety endpoints, particularly the rate of drug discontinuation due to adverse events, and patient-reported outcomes, including quality of life measured by the AF-QoL questionnaire, will be systematically collected and compared between the two groups.

• Atrial Fibrillation (AF)

• Dronedarone
• flecainide
• propafenone

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Participants who have voluntarily provided written informed consent to participate.
• Adults aged 19 years or older.
• Life expectancy of at least 1 year.
• Diagnosis of atrial fibrillation within the past 1 year.
• Participants with an indication for antiarrhythmic drug therapy (Dronedarone or Class Ic agents).

Exclusion Criteria:

• History of failure with prior antiarrhythmic drug therapy.
• Confirmed severe structural heart disease (e.g., heart failure with reduced ejection fraction [LVEF <= 40%], moderate or severe mitral stenosis, mechanical heart valve replacement, or dilated cardiomyopathy).
• Diagnosis of permanent atrial fibrillation.
• Severe renal impairment (eGFR < 30 mL/min/1.73m^2 or on dialysis) or severe hepatic impairment (Child-Pugh class B or higher) that restricts the use of antiarrhythmic drugs.
• Known contraindications to dronedarone or Class Ic antiarrhythmic drugs.
• Participation in another clinical trial within 3 months prior to randomization.
• Participants who do not agree to refrain from participating in another clinical trial within 14 days after their participation in this study ends.
• Pregnant or breastfeeding women, or women of childbearing potential who do not agree to use effective contraception during the study.
• Any other condition that, in the opinion of the investigator, makes the participant unsuitable for study participation.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Inha University HospitalOTHER

osm221001@gmail.com+82-31-412-5114

euna0725@naver.com+82-51-990-6114

crcsrk8610@nhimc.or.kr+82-31-900-3931

04145019@hanmail.net+82-31-810-5114

igysa@korea.ac.kr+82-2-920-6710

cardiocrc66@yuhs.ac+82-1599-1004

grkmcgrca009@kumc.or.kr+82-2--2626-2336